Logos Global Management LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Logos Global Management LP reported 49 stock positions worth $950.2 million. Its top holding was Ideaya Biosciences (IDYA) at 6.9% of the portfolio, followed by Immunocore Holdings PLC-ADR (IMCR, 6.2%) and Immunovant (IMVT, 6.0%). Compared with Q4 2023, it opened 23 new positions, sold out of 20, added to 9 and reduced 10. The biggest buy was a new position in Sarepta Therapeutics (SRPT) and the biggest sale Cytokinetics (CYTK, shares −94%).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $950.2M (Q1 2024)
- SEC Filing
- 0001172661-24-002503 ↗ filed May 15, 2024
Holdings Value
Holdings 49 stocks · $950.2M
| IDYA Ideaya Biosciences Inc. | 6.93% | 1,500,000 | $65.8M | Reduce -16.7% |
| IMCR Immunocore Holdings PLC-ADR | 6.16% | 900,000 | $58.5M | Add +125.0% |
| IMVT Immunovant Inc. | 6.04% | 1,775,000 | $57.4M | Add +47.9% |
| OCUL Ocular Therapeutix Inc. | 5.47% | 5,811,436 | $52.0M | Add +45.3% |
| SRPT Sarepta Therapeutics Inc. | 5.45% | 400,000 | $51.8M | New |
| OLMA Olema Pharmaceuticals Inc. | 5.22% | 4,383,875 | $49.6M | No change |
| DYN Dyne Therapeutics Inc. | 5.17% | 1,730,000 | $49.1M | Reduce -8.0% |
| APLS Apellis Pharmaceuticals Inc. | 4.95% | 800,000 | $47.0M | Reduce -15.8% |
| RCKT Rocket Pharmaceuticals Inc. | 3.69% | 1,300,000 | $35.0M | Add +2.0% |
| SLN Silence Therapeutics PLC-ADR | 3.27% | 1,476,061 | $31.1M | Add +269.0% |
| GPCR Structure Therapeutics Inc. | 3.25% | 720,058 | $30.9M | Reduce -32.7% |
| GERN Geron Corp. | 3.13% | 9,000,000 | $29.7M | New |
| CLDX Celldex Therapeutics Inc. | 2.87% | 650,000 | $27.3M | New |
| ELVN Enliven Therapeutics Inc. | 2.78% | 1,574,220 | $26.4M | Add +412.6% |
| VERA Vera Therapeutics Inc. | 2.61% | 575,000 | $24.8M | New |
| ANNX Annexon Inc. | 2.30% | 3,050,000 | $21.9M | Reduce -38.4% |
| ADVM Adverum Biotechnologies Inc. | 2.23% | 1,499,999 | $21.2M | New |
| DSGN Design Therapeutics Inc. | 2.13% | 5,032,501 | $20.3M | No change |
| AKRO Akero Therapeutics Inc. | 2.13% | 800,000 | $20.2M | No change |
| ATXS Astria Therapeutics Inc. | 1.84% | 1,244,960 | $17.5M | Add +128.4% |
| CYBIN INC | 1.74% | 40,000,000 | $16.5M | New |
| XNCR Xencor Inc. | 1.51% | 650,000 | $14.4M | New |
| CGON CG Oncology Inc. | 1.39% | 300,000 | $13.2M | New |
| ENGN Engene Holdings Inc. | 1.36% | 800,000 | $12.9M | New |
| KYTX Kyverna Therapeutics Inc. | 1.31% | 500,000 | $12.4M | New |
| VRDN Viridian Therapeutics Inc. | 1.29% | 700,000 | $12.3M | Add +16.7% |
| CGEM Cullinan Therapeutics Inc. | 1.26% | 700,000 | $11.9M | New |
| IMTX Immatics NV | 1.11% | 1,000,000 | $10.5M | New |
| SYRE Spyre Therapeutics Inc. | 1.00% | 250,000 | $9.5M | Add +66.7% |
| LCTX Lineage Cell Therapeutics Inc. | 0.97% | 6,250,000 | $9.3M | New |
| PRAX Praxis Precision Medicines I | 0.96% | 150,000 | $9.2M | New |
| APLT Applied Therapeutics Inc. | 0.94% | 1,350,000 | $9.0M | Reduce -18.7% |
| SNDX Syndax Pharmaceuticals Inc. | 0.88% | 350,000 | $8.3M | New |
| TRVI Trevi Therapeutics Inc. | 0.80% | 2,200,000 | $7.6M | New |
| CYTK Cytokinetics Inc. | 0.74% | 100,000 | $7.0M | Reduce -93.8% |
| KURA Kura Oncology Inc. | 0.67% | 300,000 | $6.4M | New |
| NMRA Neumora Therapeutics Inc. | 0.65% | 382,345 | $6.2M | No change |
| ATYR Atyr Pharma Inc. | 0.64% | 3,100,000 | $6.0M | Reduce -47.0% |
| JANX Janux Therapeutics Inc. | 0.59% | 150,000 | $5.6M | New |
| ELEV Elevation Oncology Inc. | 0.54% | 1,000,000 | $5.1M | New |
| NXTC Nextcure Inc. | 0.45% | 1,925,000 | $4.3M | New |
| ALLK Allakos LLC | 0.38% | 2,900,000 | $3.7M | No change |
| UNICYCIVE THERAPEUTICS INC | 0.32% | 3,469,927 | $3.0M | New |
| BOLD Boundless Bio Inc. | 0.30% | 200,000 | $2.9M | New |
| TRML Tourmaline Bio Inc. | 0.24% | 99,208 | $2.3M | Reduce -65.1% |
| CMPS Compass Pathways PLC | 0.19% | 257,980 | $1.8M | Reduce -48.4% |
| IOBTQ Io Biotech Inc. | 0.09% | 493,827 | $854K | No change |
| IMUX Immunic Inc. | 0.06% | 421,184 | $556K | No change |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.01% | 39,500 | $105K | New |
Options reported separately and not counted above: SRPT calls ($155.4M), ALNY calls ($74.7M), GPCR calls ($19.3M), ATXS calls ($14.1M), FULC calls ($9.4M), ANNX calls ($7.2M), LRMR calls ($5.3M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $23K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $23K | No change |
Total filed on the 13F, all lines: $950.2M.
Portfolio Sells Q4 2023 → Q1 2024
| CYTK Cytokinetics Inc. | Reduce -93.8% | 0.74% | −14.35 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −6.13 |
| RYZB Rayzebio Inc. | Sold out | 0.00% | −3.93 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −3.33 |
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −3.17 |
| MOR Morphosys AG ADR | Sold out | 0.00% | −1.62 |
| GPCR Structure Therapeutics Inc. | Reduce -32.7% | 3.25% | −1.60 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -15.8% | 4.95% | −1.37 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −1.16 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −1.12 |
| SLRN Acelyrin Inc. | Sold out | 0.00% | −1.04 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −1.01 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.90 |
| RNAM Avidity Biosciences Inc. | Sold out | 0.00% | −0.78 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −0.77 |
| RCUS Arcus Biosciences Inc. | Sold out | 0.00% | −0.69 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −0.64 |
| TRML Tourmaline Bio Inc. | Reduce -65.1% | 0.24% | −0.59 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.55 |
| ICVX Icosavax Inc. | Sold out | 0.00% | −0.53 |
| RPTX Repare Therapeutics Inc. | Sold out | 0.00% | −0.49 |
| INHIBRX INC | Sold out | 0.00% | −0.42 |
| CMPS Compass Pathways PLC | Reduce -48.4% | 0.19% | −0.30 |
| KNSA Kiniksa Pharmaceuticals Ltd. | Sold out | 0.00% | −0.29 |
| ATYR Atyr Pharma Inc. | Reduce -47.0% | 0.64% | −0.28 |
| ANNX Annexon Inc. | Reduce -38.4% | 2.30% | −0.20 |
| IDYA Ideaya Biosciences Inc. | Reduce -16.7% | 6.93% | −0.19 |
| DCTH Delcath Systems Inc. | Sold out | 0.00% | −0.14 |
| APLT Applied Therapeutics Inc. | Reduce -18.7% | 0.94% | +0.33 |
| DYN Dyne Therapeutics Inc. | Reduce -8.0% | 5.17% | +2.39 |
Portfolio Buys Q4 2023 → Q1 2024
| SRPT Sarepta Therapeutics Inc. | New | 5.45% | +5.45 |
| OCUL Ocular Therapeutix Inc. | Add +45.3% | 5.47% | +3.49 |
| GERN Geron Corp. | New | 3.13% | +3.13 |
| IMCR Immunocore Holdings PLC-ADR | Add +125.0% | 6.16% | +3.12 |
| CLDX Celldex Therapeutics Inc. | New | 2.87% | +2.87 |
| VERA Vera Therapeutics Inc. | New | 2.61% | +2.61 |
| SLN Silence Therapeutics PLC-ADR | Add +269.0% | 3.27% | +2.50 |
| ELVN Enliven Therapeutics Inc. | Add +412.6% | 2.78% | +2.31 |
| ADVM Adverum Biotechnologies Inc. | New | 2.23% | +2.23 |
| CYBIN INC | New | 1.74% | +1.74 |
| XNCR Xencor Inc. | New | 1.51% | +1.51 |
| CGON CG Oncology Inc. | New | 1.39% | +1.39 |
| ATXS Astria Therapeutics Inc. | Add +128.4% | 1.84% | +1.38 |
| ENGN Engene Holdings Inc. | New | 1.36% | +1.36 |
| KYTX Kyverna Therapeutics Inc. | New | 1.31% | +1.31 |
| CGEM Cullinan Therapeutics Inc. | New | 1.26% | +1.26 |
| IMTX Immatics NV | New | 1.11% | +1.11 |
| LCTX Lineage Cell Therapeutics Inc. | New | 0.97% | +0.97 |
| PRAX Praxis Precision Medicines I | New | 0.96% | +0.96 |
| SNDX Syndax Pharmaceuticals Inc. | New | 0.88% | +0.88 |
| TRVI Trevi Therapeutics Inc. | New | 0.80% | +0.80 |
| KURA Kura Oncology Inc. | New | 0.67% | +0.67 |
| SYRE Spyre Therapeutics Inc. | Add +66.7% | 1.00% | +0.64 |
| JANX Janux Therapeutics Inc. | New | 0.59% | +0.59 |
| ELEV Elevation Oncology Inc. | New | 0.54% | +0.54 |
| NXTC Nextcure Inc. | New | 0.45% | +0.45 |
| IMVT Immunovant Inc. | Add +47.9% | 6.04% | +0.41 |
| UNICYCIVE THERAPEUTICS INC | New | 0.32% | +0.32 |
| BOLD Boundless Bio Inc. | New | 0.30% | +0.30 |
| CYPH Cypherpunk Technologies Inc. | New | 0.01% | +0.01 |
| VRDN Viridian Therapeutics Inc. | Add +16.7% | 1.29% | −0.16 |
| RCKT Rocket Pharmaceuticals Inc. | Add +2.0% | 3.69% | −0.56 |
Options Activity Q4 2023 → Q1 2024
| SRPT Sarepta Therapeutics Inc. | call | Add +71.4% | 1,200,000 | $155.4M |
| ALNY Alnylam Pharmaceuticals Inc. | call | New | 500,000 | $74.7M |
| APLS Apellis Pharmaceuticals Inc. | call | Sold out | 1,000,000 | $59.9Mbefore exit |
| GPCR Structure Therapeutics Inc. | call | New | 450,000 | $19.3M |
| INHIBRX INC | call | Sold out | 500,000 | $19.0Mbefore exit |
| ATXS Astria Therapeutics Inc. | call | New | 1,000,000 | $14.1M |
| MOR Morphosys AG ADR | call | Sold out | 1,000,000 | $9.9Mbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | New | 1,000,000 | $9.4M |
| IOVA Iovance Biotherapeutics Inc. | call | Sold out | 1,000,000 | $8.1Mbefore exit |
| ZNTL Zentalis Pharmaceuticals Inc. | call | Sold out | 500,000 | $7.6Mbefore exit |
| ANNX Annexon Inc. | call | New | 1,000,000 | $7.2M |
| LRMR Larimar Therapeutics Inc. | call | New | 700,000 | $5.3M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |